Literature DB >> 24092570

HDAC5 promotes osteosarcoma progression by upregulation of Twist 1 expression.

Jie Chen1, Jun Xia, Yong-lin Yu, Si-qun Wang, Yi-bing Wei, Fei-yan Chen, Gang-yong Huang, Jing-sheng Shi.   

Abstract

Histone deacetylases (HDACs) form a family of enzymes, which have fundamental roles in the epigenetic regulation of gene expression and contribute to the growth, differentiation, and apoptosis of cancer cells. In this study, we firstly investigated the biological function of HDAC5 in osteosarcoma cells. We found that mRNA and protein levels of HDAC5 were upregulated in osteosarcoma tissues and cell lines. Furthermore, overexpression of HDAC5 could promote cell proliferation in osteosarcoma cell lines. In contrast, HDAC5 knockdown using small interfering RNA inhibited cell proliferation. At the molecular level, we demonstrated that HDAC5 promoted mRNA expression of twist 1, which has been reported as an oncogene. Together, these results highlighted for the first time an unrecognized link between HDAC5 and osteosarcoma progression and demonstrated that its specific inhibition might contribute to the treatment of tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24092570     DOI: 10.1007/s13277-013-1189-x

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  23 in total

1.  Isolation of a novel histone deacetylase reveals that class I and class II deacetylases promote SMRT-mediated repression.

Authors:  H Y Kao; M Downes; P Ordentlich; R M Evans
Journal:  Genes Dev       Date:  2000-01-01       Impact factor: 11.361

Review 2.  Osteosarcoma: anatomic and histologic variants.

Authors:  Michael J Klein; Gene P Siegal
Journal:  Am J Clin Pathol       Date:  2006-04       Impact factor: 2.493

3.  Altered interaction of HDAC5 with GATA-1 during MEL cell differentiation.

Authors:  Kouichi Watamoto; Masayuki Towatari; Yukiyasu Ozawa; Yasuhiko Miyata; Mitsunori Okamoto; Akihiro Abe; Tomoki Naoe; Hidehiko Saito
Journal:  Oncogene       Date:  2003-12-11       Impact factor: 9.867

4.  Oncogenic cooperation between H-Twist and N-Myc overrides failsafe programs in cancer cells.

Authors:  Sandrine Valsesia-Wittmann; Maud Magdeleine; Sébastien Dupasquier; Elisabeth Garin; Anne-Catherine Jallas; Valérie Combaret; Alexander Krause; Philippe Leissner; Alain Puisieux
Journal:  Cancer Cell       Date:  2004-12       Impact factor: 31.743

5.  Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases.

Authors:  A Lahm; C Paolini; M Pallaoro; M C Nardi; P Jones; P Neddermann; S Sambucini; M J Bottomley; P Lo Surdo; A Carfí; U Koch; R De Francesco; C Steinkühler; P Gallinari
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-23       Impact factor: 11.205

Review 6.  Osteosarcoma: Conventional treatment vs. gene therapy.

Authors:  Mei Lin Tan; Peter F M Choong; Crispin R Dass
Journal:  Cancer Biol Ther       Date:  2009-02-12       Impact factor: 4.742

7.  Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence.

Authors:  Stéphane Ansieau; Jeremy Bastid; Agnès Doreau; Anne-Pierre Morel; Benjamin P Bouchet; Clémence Thomas; Frédérique Fauvet; Isabelle Puisieux; Claudio Doglioni; Sara Piccinin; Roberta Maestro; Thibault Voeltzel; Abdelkader Selmi; Sandrine Valsesia-Wittmann; Claude Caron de Fromentel; Alain Puisieux
Journal:  Cancer Cell       Date:  2008-07-08       Impact factor: 31.743

8.  von Willebrand factor expression in osteosarcoma metastasis.

Authors:  Kolja Eppert; Jay S Wunder; Vicky Aneliunas; Rita Kandel; Irene L Andrulis
Journal:  Mod Pathol       Date:  2005-03       Impact factor: 7.842

9.  Histone deacetylase 5 represses the transcription of cyclin D3.

Authors:  Sangita Roy; Audrey C Shor; Tapan K Bagui; Edward Seto; W Jackson Pledger
Journal:  J Cell Biochem       Date:  2008-08-15       Impact factor: 4.429

10.  Twist promotes tumor cell growth through YB-1 expression.

Authors:  Masaki Shiota; Hiroto Izumi; Takamitsu Onitsuka; Naoya Miyamoto; Eiji Kashiwagi; Akihiko Kidani; Akira Yokomizo; Seiji Naito; Kimitoshi Kohno
Journal:  Cancer Res       Date:  2008-01-01       Impact factor: 12.701

View more
  7 in total

Review 1.  Therapeutic applications of histone deacetylase inhibitors in sarcoma.

Authors:  Fan Tang; Edwin Choy; Chongqi Tu; Francis Hornicek; Zhenfeng Duan
Journal:  Cancer Treat Rev       Date:  2017-07-06       Impact factor: 12.111

2.  HDAC5 promotes colorectal cancer cell proliferation by up-regulating DLL4 expression.

Authors:  Ping He; Jiexiong Liang; Tiansong Shao; Yang Guo; Yingchen Hou; Yang Li
Journal:  Int J Clin Exp Med       Date:  2015-04-15

3.  Proteomic and transcriptomic profiles of human urothelial cancer cells with histone deacetylase 5 overexpression.

Authors:  Ananda Ayyappan Jaguva Vasudevan; Michèle J Hoffmann; Gereon Poschmann; Patrick Petzsch; Constanze Wiek; Kai Stühler; Karl Köhrer; Wolfgang A Schulz; Günter Niegisch
Journal:  Sci Data       Date:  2022-05-27       Impact factor: 8.501

4.  Formononetin sensitizes glioma cells to doxorubicin through preventing EMT via inhibition of histone deacetylase 5.

Authors:  Quan Liu; Yan Sun; Jie-Min Zheng; Xian-Lei Yan; Hong-Mou Chen; Jia-Kang Chen; He-Qing Huang
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

5.  [Twist regulates proliferation, migration and invasion of osteosarcoma cells in vitro].

Authors:  Yun He; Shu-Yu Fang; Yang Bi; Tong-Chuan He; Yi Wang; Si-Qi Hong
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-05-20

6.  METTL3 stabilizes HDAC5 mRNA in an m6A-dependent manner to facilitate malignant proliferation of osteosarcoma cells.

Authors:  Renbing Jiang; Zhibing Dai; Junshen Wu; Suzhi Ji; Yachao Sun; Wenpeng Yang
Journal:  Cell Death Discov       Date:  2022-04-08

Review 7.  Insights Into the Function and Clinical Application of HDAC5 in Cancer Management.

Authors:  Jun Yang; Chaoju Gong; Qinjian Ke; Zejun Fang; Xiaowen Chen; Ming Ye; Xi Xu
Journal:  Front Oncol       Date:  2021-06-10       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.